1. Scrip

Stock Watch: Intellia Edits Out The Competition

Significant Gene Editing Efficacy Gives Edge Over Traditional Gene Therapy

 
• By Andy Smith

Exciting early results in gene editing contrast with issues around traditional gene therapies, including non-responders, safety and questions over the duration of efficacy.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

At the recent European Academy of Allergy and Clinical Immunology Congress,Intellia Therapeutics, Inc. announced an update of the first part of the Phase I/II study of its CRISPR/Cas9 gene editing product NTLA-2002 for the prevention of inflammatory attacks in hereditary angioedema (HAE) patients. (Also see "Stock Watch: Not So Fast, Gene Editors" - Scrip, 5 July, 2021.)

The aim of NTLA-2002 is to inactivate the kallikrein B1 gene because C1 esterase inhibitor deficiency in HAE patients leaves...

More from Stock Watch

More from Business

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 
• By Alaric DeArment

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By Mandy Jackson

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By Andy Smith

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.